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Abstract
Objective—To investigate the expression level of prostaglandins (PGs) and their de novo
synthesis in dry eye (DE) disease.
Design—Cross-sectional case-control study and in vivo mouse experimental study.
Participants—Forty-six eyes from 23 DE patients and 33 eyes from 17 age- and sex-matched
controls were studied. Also, DE-induced murine eyes were compared with control eyes.
Methods—Patients completed a symptom questionnaire using a 100-mm visual analog scale
(VAS). Nanoliquid chromatography tandem mass spectrometry was used for the quantification of
PGE2 and PGD2. A DE disease environmental chamber was used to induce DE in mice. One
week after induction, enzyme expressions of cyclooxygenase-1, cyclooxygenase-2 (COX-2), PG E
synthase (PGES), and PG D synthase (PGDS) in the lacrimal glands, meibomian glands, and
corneas were examined using immunohistochemistry and quantitative real-time polymerase chain
reaction (qRT-PCR).
Main Outcome Measures—The mean PGE2 and PGD2 levels in the tears of DE patients were
measured and compared with symptom severity scores. Immunohistochemistry staining patterns
and qRT-PCR data of DE mice were quantified.
Results—The mean PGE2 level in the tears of DE patients (2.72±3.42 ng/ml) was significantly
higher than that in the control group (0.88±0.83 ng/ml; P = 0.003). However, the mean PGD2
level in the tears of DE patients (0.11 ±0.22 ng/ml) was significantly lower (0.91 ±3.28 ng/ml; P =
0.028). The mean PGE2-to-PGD2 ratio correlated strongly with VAS scoring (P = 0.008). In DE
mice, COX-2 mRNA was significantly higher in ocular surface tissue and lacrimal glands.
Furthermore, PGES mRNA was significantly higher in ocular surface tissue, whereas PGDS
mRNA was decreased. Immunohistochemistry staining showed elevated COX-2 expression in the
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lacrimal glands, meibomian glands, corneas, and conjunctivas. Furthermore, PGES expression was
found in periductal infiltrated cells of the lacrimal glands and conjunctival epithelium. Also,
PGDS expression was decreased in meibomian glands and increased focally in the conjunctival
epithelium.
Conclusions—A reciprocal change in PGE2 and PGD2 levels was found in the tears of DE
patients, which correlated with patients’ symptom scores. These clinical results were supported by
increased COX-2 and PGES expression levels found in tear-producing tissues of DE mice.
Financial Disclosure(s)—The author(s) have no proprietary or commercial interest in any
materials discussed in this article.
Patients with dry eye (DE) disease typically have symptoms of ocular discomfort ranging
from irritation to severe pain.1,2 There is an intuitive causal link between the signs of DE
observed by clinicians and the severity of symptoms experienced by patients. However, this
expectation is challenged by asymptomatic patients with obvious tear film anomalies and
extensive ocular surface comprise and, conversely, by patients with intolerable symptoms of
dryness in whom only minimal disease can be observed.3 Moreover, reliable diagnostic tests
to assess symptoms and clinical signs for DE remain controversial. In most clinical
practices, DE is evaluated and managed largely on the basis of patients’ symptoms.3,4
The cornea is highly innervated by sensory nerves that serve important sensory and reflex
functions.5 Despite the lack of morphologic specialization at the nerve endings, different
functional sensory fibers, including polymodal nociceptors, mechanonociceptors, and
thermoreceptors, have been identified based on electrophysiologic studies.6–8 Generally,
activation of thermoreceptors results in a sensation of cooling, whereas activation of
mechanoreceptors or polymodal receptors results in ocular surface discomfort and pain.9
When noxious stimuli activate sensory afferents in the functional units, a series of
coordinated reflexes, including reflex tearing, are triggered to protect the eye from potential
damage.10 Nociceptors generally are silent electrically and transmit all-or-none action
potentials only when stimulated.11 To activate nociceptors, proper and adequate stimuli are
required. Heat or cold, intense pressure or squeezing, and irritating chemicals can result in
depolarizing nociceptor terminals.11,12 The known chemical nociceptor activators are
capsaicin, bradykinin, histamine, and prostaglandin (PG).11–16
Prostaglandins are short-lived lipid mediators that exert a multitude of biological functions.
They are synthesized from arachidonic acid after its mobilization from the cell membrane
after a host of stimuli, including inflammatory stimuli.17 Use of PG analogs (e.g.,
latanoprost) in ocular disease showed that these drugs cause ocular inflammation and
various side effects in ocular tissues.18,19 Common side effects of PG analogs are ocular
pain, discomfort, and conjunctival injection, which are the prevalent symptoms of DE.20
Increased levels of proinflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor
necrosis factor α have been detected in the tear fluid and conjunctival epithelium of DE
patients.4,21 Interestingly, for the induction of PGs, inflammatory stimuli such as IL-1 are
known to induce cyclooxygenase (COX) and PG rapidly.22 Moreover, a previous
population-based study reported that subjects who took oral aspirin for managing
atherosclerosis and hypertension reported low DE symptoms and signs.23 Despite the
inflammatory nature of DE, the level of PGs and the exact role of PGs in DE have not been
determined.
This study investigates PG levels, including PGE2, PGD2, and PGI2, in DE patients and
determines whether different levels of PGs are related to subjective symptom scores. In
addition, the level of PG synthesizing enzymes in ocular surfaces and lacrimal glands was
investigated using an induced mouse environmental chamber model of DE.
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Patients and Methods
Patients and Examinations
The study was conducted at 2 independent sites. The cross-sectional, case-control clinical
trial was conducted at the Severance Hospital, Department of Ophthalmology, Yonsei
University College of Medicine, Seoul, Korea. The in vivo animal DE work was performed
at Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts. All
procedures conformed to the tenets of the Declaration of Helsinki, and informed consent
was obtained from all patients after gaining approval from the institutional review board. A
total of 23 non–Sjögren-type DE patients completed the study (9 men, 14 women), with a
mean age±standard deviation of 57.0±12.9 years (range, 35–84 years). Inclusion criteria
were: 1 or more DE-related symptoms, including tightness, foreign body sensation,
irritation, red eye, itching sensation, blurring, or pain; Schirmer test results (with anesthesia)
of 8 mm in 5 minutes or less in both eyes; tear film break-up time of 5 seconds or less in
both eyes; and typical keratoconjunctivitis sicca pattern of superficial punctuate erosion of
conjunctiva or cornea. Patients were excluded for history of using any eye drops in the most
recent month; infection or trauma; ocular or other surgery within the previous 6 months;
severe blepharitis with meibomian gland dysfunction; blinking abnormality (e.g.,
Parkinson’s disease, facial nerve palsy); severe pterygium or uncontrolled systemic disease;
or if they were pregnant or lactating. The control group comprised 33 eyes from 17 age- and
sex-matched healthy subjects (6 men, 11 women) who had no history of ocular or systemic
diseases, no subjective symptoms of ocular surface dryness, a tear film break-up time of
more than 8 seconds, and a Schirmer value of more than 10 mm per 5 minutes. The mean
age of control subjects was 53.0±17.0 years (range, 26–73 years). The demographic data for
included patients are in Table 1 (available at http://aaojournal.org).
For baseline evaluation, tear film break-up time, Schirmer test, fluorescein staining using
biomicroscopy, tear sampling, and intraocular pressure were measured in both eyes of DE
patients and of healthy normal controls. Symptom severity scores also were obtained using
the visual analog scale (VAS) from DE patients who were instructed to grade their
symptoms on a 10-cm bar scale (0 cm, no symptoms; 10 cm, severe and intolerable pain)
and to evaluate right and left eyes separately. To determine the ocular pain susceptibility and
threshold between healthy controls and DE patients, standard pH solutions (pH 4.5–7.0)
were prepared at 0.5-scale intervals with a phosphate buffer-based formula (Samil-Allergan,
Inc., Seoul, Korea), and 1 drop of each pH solution from pH 7.0 to the lower pH values were
administered into the eye. The threshold of ocular irritation at the pH when patients first
reported irritation and the suprathreshold at 0.5 units lower than the threshold were
measured.
During the test period, all evaluations were performed in a masked fashion. The DE
classification and tear sampling were performed by one author (C.P.). Another author (J.S.),
who was blinded to healthy control or DE status, evaluated threshold and pain scores at the
suprathreshold of the patients. Blinded data were analyzed by another author (H.K.L.).
Tear Sampling and Measurement of Prostaglandin E2, Prostaglandin D2, and
Prostaglandin I2
To measure the concentration of PGs E2, D2, and I2 in tears, a bonDE 2.0×10-mm polyester
fiber rod (Transorb Wicks; Filtrona, Richmond, VA) was used to collect tear fluid as
reported previously.24 A polyester wick was introduced into the lower conjunctival sac and
was removed and placed in a 1.5-ml Eppendorf tube, which was stored at −70°C until mass
spectrophotometric assay. All nano-liquid chromatography tandem mass spectrometry
experiments were carried out on an Applied Biosystem/MDS Sciex 4000 Qtrap quadrupole
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mass spectrometer (AB/MDS Sciex, Concord, Canada) equipped with a turboion spray
source. The mass spectrometer was coupled to an Agilent 1200 series high-performance
liquid chromatography system (Agilent Technologies, Santa Clara, CA). Data were acquired
and processed using Analyst software (version 1.4.2; AB/MDS Sciex). Chromatographic
separation was achieved with a Synergi Hydro-RP (C18) 50×2.1-mm inner diameter, 4-µm
80-Å (angstrom units) particles column (Phenomenex, Torrance, CA) at 40°C. The analysis
time was 7 minutes and the working mass spectrometer mode was multiple reaction
monitoring. The mobile phase was a binary gradient using 40% acetonitrile as solution A
and 100% methanol as solution B at a 60:40 (volume/volume) ratio. The flow rate was 0.6
ml/minute.
Induction of Dry Eye and Securing Eye and Ocular Adnexal Tissues Using a Mouse Dry
Eye Chamber Model
Female (C57BL/6) mice 6 to 8 weeks of age (Charles River Laboratory, Wilmington MA)
were used in accordance with the standards in the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The
research protocol was approved by the Schepens Eye Research Institute Animal Care and
Use Committee. As described previously, DE was induced in the mice by placing them in a
controlled environment chamber.25 To achieve maximum ocular surface dryness, in addition
to the controlled environment chamber, the mice were given subcutaneous injections of 0.1
ml scopolamine hydrobromide, 5 mg/ml (Sigma-Adlrich Chemical Co., St. Louis, MO), 3
times daily for the duration of the experiment.
During the DE induction, the mice were killed at 3 days and 7 days after induction. The lids,
eyeballs, and lacrimal glands were collected. Each tissue was halved, with half fixed with
3.7% paraformaldehyde and stored until immunostaining. The other half was stored at
−70°C for quantitative real-time polymerase chain reaction analysis. To investigate the
effect of COX-2 inhibitor, 3 different concentrations of celecoxib (Sigma-Aldrich, Inc.)
solution (0.1 µg/ml, 1.0 µg/ml, and 10.0 µg/ml) were administered into 6 eyes of 3 mice 3
times daily for 1 week in 2-week DE-induced mice.
Immunohistochemical Staining for Prostaglandins
Lids, conjunctivas, corneas, and lacrimal glands were harvested and analyzed by
immunohistochemical staining. Four to 6 eyeballs with lids and lacrimal glands from 4 to 6
mice were used for each antibody of each group (control and DE-induced group). Histologic
sections (5 to 7 µm) were collected on poly-L-lysine–coated slides and deparaffinized, and
sections were rehydrated with a xylene-grade alcohol scale and were rinsed with phosphate-
buffered saline. Intrinsic peroxidase activity was blocked with 3% H2O2 for 5 minutes at
room temperature, and the sections were exposed to primary antibodies: rat monoclonal
antimouse COX-1 (Cayman, Ann Arbor, MI), COX-2 (Abcam, Cambridge, UK), PGE
synthase (PGES; Cayman, Ann Arbor, MI), or PGD synthase (PGDS; Cayman, Ann Arbor,
MI). All antibodies were diluted 1:300 and were incubated overnight. After washing in
0.05% Tween 20, sections were exposed to universal biotin-conjugated antibodies for 30
minutes at room temperature. Sections were incubated with peroxidase-conjugated
streptavidin for 20 minutes at room temperature. Color development was carried out with
diaminobenzidine chromogen and 0.05% H2O2. Sections were counterstained with Meyer’s
hematoxylin (DAKO, Glostrup, Denmark). Human skin and colon tissue were used as
positive controls. Light microscope (Axio Imager 2, Carl Zeiss, Oberkochen, Germany) was
used for examination.
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Tissue RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Four to 6 corneas and lacrimal glands from 4 to 6 mice were involved in each group
(control, 3-day DE induction, 7-day DE induction, and varying celecoxib concentration
groups). Each experiment was repeated 3 times. RNA was isolated with RNeasy Micro Kit
(Qiagen, Hilden, Germany) from mouse corneas and lacrimal glands and reverse transcribed
using a Superscript III Kit (Invitrogen, Carlsbad, CA). Quantitative real-time polymerase
chain reaction was performed using Taq-Man Universal PCR Mastermix and preformulated
primers for COX-1 (Mm04225243_g1; Applied Biosystems, Foster City, CA), COX-2
(Mm03294838_g1), PGE2 synthase (Mm00452105_m1), PGD2 synthase
(Mm01330613_m1), and GAPDH (Mm99999915_g1).
Statistical Analysis
Basic characteristics of the study population, including healthy controls and DE patients,
were reported for each variable by descriptive statistics using the Fisher exact test for
frequency data, the t test for continuous data, and the Mann–Whitney U test for nonnormally
distributed data. Correlations of ocular irritation scores and concentration of PGE2-to-PGD2
were analyzed by linear regression analysis with a 95% confidence interval. The 1-way
analysis of variance was used to assess mRNA expression. All statistical tests were 2-sided
at the 95% confidence interval and were performed using the SAS software version 9.13
(SAS Inc, Cary, NC).
Results
Prostaglandin E2, Prostaglandin D2, and Prostaglandin I2 Concentration in Dry Eye Patient
Tears
In DE patients, PGE2 concentration demonstrated a 3.1-fold increase compared with normal
controls (mean±standard deviation, 2.72±3.42 ng/ml vs. 0.88±0.83 ng/ml; P = 0.003; Fig
1A). However, PGD2 was significantly decreased in DE patients (0.11±0.22 ng/ml)
compared with normal controls (0.91±3.28 ng/ml; P = 0.028; Fig 1B). In both normal
controls and DE patients, PGI2 was not detected. Some representative liquid
chromatography tandem mass spectrometry profiles are shown in Figure 2 (available at
http://aaojournal.org).
Correlation of Patients’ Ocular Irritation Symptoms and Prostaglandin Levels
Prostaglandin E2 is an inflammatory autacoid that elicits pain or irritative symptoms by
lowering the nerve ending firing threshold.26 Therefore, whether patients’ symptom scores
correlated with tear PG levels was determined. Although PGE2 or PGD2 concentrations
alone did not correlate with symptom score values (Table 2), the ratio of PGE2-to-PGD2
levels correlated significantly with the VAS score. The DE patients with a higher VAS score
tended to have high PGE2-to-PGD2 ratios in their tears.
To determine the effect of PGE2-to-PGD2 levels on nerve terminal firing by an irritation
stimulus, an ocular stimulation challenge test was carried out using standard pH solutions.
Because a commercial antiglaucoma medication pH is 5.6, the standard solution was
prepared from 5.0 to 8.0, with a 0.5-unit scale. From the challenge test, DE and normal
controls felt ocular irritation at similar pH values (pH 5.59±0.49 and pH 5.68±0.40,
respectively; P = 0.63) with the same intensity (VAS score, 1.81 ±0.98 vs. 1.73±1.19; P =
0.84; Fig 3, available at http://aaojournal.org). However, the intensity of irritation was much
higher for DE patients (2.41 ±1.46) than normal patients (1.31±0.60) at suprathreshold
levels (challenged by 0.5 pH units lower than the threshold; P = 0.012; Fig 3, available at
http://aaojournal.org).
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mRNA of Cyclooxygenase-1, Cyclooxygenase-2, Prostaglandin E2 Synthase, and
Prostaglandin D2 Synthase in Dry Eye Mice
Dry eye patients had higher PGE2-to-PGD2 levels in their tears. Because the study of
human tissue was not feasible, PG enzyme production in the ocular surface and lacrimal
glands of a DE mouse model was investigated. In these tissues, COX-2 and PGE mRNA
levels were elevated significantly in DE mice compared with normal mice (P<0.001; Fig 4).
At 3 days after DE stimulus, COX-2 activity was higher than at 7 days (Fig 4). The PGE
mRNA levels in the cornea also were elevated by a DE environment. In contrast to COX-2
and PGES, PGDS mRNA was decreased significantly at 3 and 7 days in the DE condition
(Fig 4). However, COX-1 mRNA did not show any difference (data not shown).
Immunohistochemical Staining for Cyclooxygenase-1, Cyclooxygenase-2, Prostaglandin
E2 Synthase, and Prostaglandin D2 Synthase in Dry Eye Mice
To define the pattern of PG production in different ocular tissues, immunohistochemical
staining for PG enzyme induction was performed, and the results are summarized in Table 3.
In DE mice, COX-2 staining was increased in the lacrimal gland, meibomian gland, and
corneal and conjunctival epithelium (Fig 5). Furthermore, COX-2 stained mainly acinar cells
of the glandular tissue and ductal epithelium of lacrimal glands (Fig 5B) and meibomian
glands (Fig 5D). In the normal corneal epithelium, COX-2 stained only basal epithelium of
the limbal area (Fig 5E). However, in the DE condition, COX-2–positive cells were found
throughout the entire epithelial layer (Fig 5F, black arrow) and some anterior stromal
keratocytes (Fig 5F, asterisk). However, although some parts of the conjunctival epithelium
showed COX-2 expression (Fig 5H, arrowhead), the COX-2 expression in the conjunctiva
was seen faintly in some epithelial cells, with few stromal staining cells showing reduced
staining intensity compared with that of the cornea.
Interestingly, PGES were not found in acinar cells of lacrimal glands in DE mice (Fig 6,
available at http://aaojournal.org). However, infiltrated cells near the secretary duct and
ductal epithelium showed PGES-positive cells (Fig 6B). Also, PGES was found in some
conjunctival cells in DE mice (Fig 6D), but not in the corneas and meibomian glands (Fig
6F).
The PGDS-positive cells were found in meibomian gland in both normal and DE conditions
(Fig 6G, H), but not in lacrimal gland acinar or ductal cells. In the ocular surface, some
conjunctival epithelial cells showed PGDS expression (Fig 6J, black arrowhead), especially
in the limbal area. However, few corneal epithelial cells were found to have PGDS in DE
mice (Fig 6L).
Effect of Topical Celecoxib on Prostaglandin E2 and Prostaglandin D2 Synthase mRNA
Levels in the Lacrimal Gland
Finally, COX-2 activity was determined by treatment with a topical COX-2 inhibitor,
celecoxib. After 2 weeks of inducing DE, 3 different concentrations of celecoxib were
applied topically to DE-induced mice eyes for another week. The COX-2 activity in the
cornea was decreased significantly by topical celecoxib at a relatively low concentration (0.1
µg/ml; P = 0.022; Fig 7A). However, in lacrimal glands, COX-2 activity was not inhibited as
effectively by celecoxib as in the cornea. A higher concentration (10 µg/ml) of celecoxib
decreased the COX-2 activity in the lacrimal gland (P = 0.048; Fig 7B).
Discussion
Because PGs are known to be involved with nociceptor excitation and have not been
measured in the ocular surface in DE, the principal goal of this study was to determine PG
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levels accurately and to assess the correlation between ocular irritation symptoms and PG
concentrations. Elevated PGE2 and downregulated PGD2 were found in tears from DE
patients. The values correlated with the patients’ irritation scores. In addition, using an in
vivo DE mouse model, the synthesizing enzymes for PGE2 were upregulated in the lacrimal
glands and ocular surfaces. However, COX-1 expression was not different between normal
and DE mice by either mRNA measurement or immunohistochemical staining, for both
corneas and lacrimal glands (data not shown). Because of the short half-life of PGs, mass
spectrometry coupled with an nano-liquid chromatography tandem mass spectrometry and a
high-performance liquid chromatography system were used. To the authors’ knowledge, this
system is currently the most accurate method for measuring small molecules with extremely
low concentrations, such as PGs. On the ocular surface, PGs were in relatively higher
concentrations, even in disease-free subjects.
Several studies have investigated the role of PGs in ocular surface diseases, including DE.
However, most focused on the anti-inflammatory role of the polyunsaturated fatty acid
phospholipase A, and PGE1.27–29 In contrast to PGE1, which has anti-inflammatory
properties, PGE2 is a PG with a significant role in inflammation.26,30 Indeed, PGE2 is a key
mediator of pain and pyresis resulting from inflammation. Therefore, inhibitors of PGE2
synthesis such as nonsteroidal anti-inflammatory drugs give relief from fever and pain.30
Although the pathophysiologic role of PGE2 in DE could not be demonstrated clearly,
considering the primary function of PGE2 in inflammation, the elevated PGE2 levels in DE
may be involved in the maintenance of nociceptor excitation and the inflammatory pain
state. The ocular surface is damaged easily by mild desiccation, inflammation, and
microbes. Damaged cells may induce PGE2 at the injured region by releasing chemical
mediators or by direct physical stimulus.3 Furthermore, PGE2 concentration at the ocular
surface may be elevated more quickly than in other tissues because of tear film evaporation
and the narrow conjunctival sac, which may prolong and worsen inflammation. Therefore,
although this hypothesis needs further investigation, compared with other body sites, even a
small amount of PGE2 is likely to be sufficient to elicit and maintain the inflammatory pain
state.
In addition, the PGE2-to-PGD2 ratio correlated better with the subjective irritation score
than the PGE2 or PGD2 concentration. Functionally, these prostanoids have opposite effects
in the inflammatory process.31,32 For instance, PGE2 and its synthesizing enzyme PGES are
involved in the generation of inflammation. However, PGDS is a protective factor in
reducing inflammatory disease, such as atherosclerosis.31 Because the synthesizing enzyme
of each prostanoid is an isomerase in the PG synthesizing pathway and the next step of
COX-2 activity in the PG synthesis pathway, the expression pattern of the prostanoids is
reciprocal.31 The elevation of one PG prevents elevation of the other, which results in
amplification of the specific effect of the elevated PG. Of note, proinflammatory stimuli
(e.g., tumor necrosis factor α) found within inflammatory lesions reduce PGD2 synthase and
increase PGE2 release.33 Thus, the relative abundance of specific prostanoids is the result of
the expression and activity of specific isomerases, and the predominant expression of PGES
over PGDS may lead to increased inflammation and irritation symptoms.
To determine the PG synthesizing enzyme activity in DE, the induction and distribution of
COX-1, COX-2, PGES, and PGDS was investigated using an in vivo mouse model. From
the quantitative real-time polymerase chain reaction results, COX-2 and PGES mRNA
levels were elevated significantly in lacrimal glands and on ocular surfaces (corneas and
conjunctivas). However, PGDS mRNA was decreased significantly in the DE condition.
Considering the clinical data, which showed elevated PGE2 levels, these result were
supportive. Several interesting results from the in vivo study were found. The first is that
both lacrimal glands and ocular surfaces induce PGs. Environmental low humidity stress is
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likely to regulate PGs and their synthesizing enzymes in the ocular surface (e.g., corneal and
conjunctiva). However, lacrimal gland PG induction also was observed. This phenomenon
may be explained by a neural network between the ocular surface and lacrimal gland.
Moreover, the upregulation of COX-2 was higher in the lacrimal glands than the ocular
surface. Taken together, the lacrimal glands produced more PGE2 than the ocular surface
and were the major sources of PGE2 resulting from desiccation stress. Therefore, the neural
network between tear-producing tissues may be critical for indirect PG induction. However,
a DE model induced by not only desiccating stress, but also injection of scopolamine, was
used. It has been reported that pharmacologic cholinergic blockade (scopolamine) stimulates
inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal
gland.34 So, it is possible that pharmacologic blockade of lacrimal secretion induced
changes of PGs in the LG. Future studies will be needed to determine what role the
pharmacologic blockade using scopolamine plays in the induction of PG synthesis.
The second interesting result is that COX-2 and PGES did not coexist in the same cells from
DE-sensitive tissues. In a previous study, the PGE2 synthesizing key enzymes, COX-2 and
PGES, were upregulated by a proinflammatory stimulus and colocalized in the same cells to
induce PGE2 effectively, as detected by immunohistochemical staining.35,36 However, in
the ocular surface and lacrimal glands, both enzymes were expressed in different types of
cells (e.g., acinar and ductal epithelial cells vs. periductal infiltrated cells of the lacrimal
gland), so PGE2 seemed to be produced by cooperative work between the lacrimal acinar,
ductal epithelial, and infiltrated inflammatory cells in the lacrimal gland or cornea and
conjunctival epithelium in the ocular surface after desiccation stress. Periductal PG synthesis
also was found in infiltrated cells. Because the infiltrated cells expressed PGES, these cells
may play a role in PGE2 induction in the lacrimal glands. Considering the topographic
expression of COX-2 and PGES in the lacrimal glands, at least some PGE2 precursors
(PGH2) may be secreted into the ducts and may convert to PGE2 in periductal infiltrated
cells. Finally, PGDS expression was found in the conjunctiva with DE stimulation.
However, the cornea expressed only COX-2. Because PGD2 and PGDS have anti-
inflammatory and protective effects against inflammatory damage, elevated PGDS activity
may make the conjunctivalepithelium more resistant to desiccation stress than the cornea.
The role of PG-induced ocular surface nerve firing in DE remains unknown. The elevated
firing activity of the corneal nociceptors may stimulate tear production to overcome surface
dryness as well as to elicit irritation symptoms. The patient population in this study was
divided by DE disease period, and it was found that PGE2 tear levels were higher in patients
with recently developed DE (DE diagnosed within 3 months) than in chronic patients (data
not shown). Moreover, the COX-2 and PGE2 mRNA levels were more elevated after 3 days
than after 7 days in the DE mouse model. Therefore, PGE2 elevation may be responsible for
the early compensatory mechanism against ocular surface desiccation to induce more tear
production. In addition to lowering the firing threshold and tear secretion, PGE2 also is a
potent inducer of inflammation, including inflammatory cell infiltration and
angiogenesis.37,38 Therefore, elevated PGE2 in DE patients may aggravate ocular surface
inflammation by inducing other inflammatory mediators.
Because enhanced excitability of primary sensory neurons in inflammation and pathologic
pain states is a major contributor to the perception of pain or irritation, specific
pharmacologic agents that specifically dampen aberrant activity are desirable for therapy.3
Therefore, COX-2 and PGE2 would be good targets for managing DE. However, the COX-2
levels in the lacrimal glands were not decreased effectively by the topical COX-2–specific
inhibitor celecoxib in the in vivo study (Fig 7). This implies that a topical approach alone
may be insufficient to reduce ocular surface PGE2 levels effectively. Moreover, the lacrimal
gland COX-2 levels are higher than the ocular surface levels and are not well controlled by
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topical drugs. Therefore, more effective ways to suppress lacrimal gland PGE2 induction
must be found to suppress its synthesis and reduce patients’ irritation symptoms adequately.
The limitation of this study is that tear PG levels were measured with a cross-sectional study
design. No studies have been published about PG level in tears in DE, so the concentration
of PGs in DE patients was measured and the induction mechanism was investigated using in
vivo studies. Use of a specific COX-2 inhibitor in a well-controlled, designed, and masked
human study is needed. Also, other substances that may cause ocular irritation, such as
substance P or bradykinin, should be investigated for their relationship to ocular irritation in
DE.
In conclusion, this study found that PGE2 levels were elevated significantly in DE patients
and correlated well with patient symptoms. Considering the function of PGE2 in nerve
receptor firing, this may be one of the main reasons for irritation symptoms and a good
therapeutic target. In addition, exploring existing knowledge about pain and noxious
substance levels may be beneficiary for DE investigators for interpreting their data and
understanding better the pathophysiologic mechanism of irritation symptoms in DE disease.
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Figure 1.
Graphs showing expression of prostaglandins (PGs) in the tears of controls (n = 33) and dry
eye patients (n = 46). Concentrations of (A) prostaglandin E (PGE2) and (B) prostaglandin
D (PGD2) were measured by nano-liquid chromatography tandem mass spectrometry. The
boxplot represents (center bar) the median, (bottom) 25%, and (top) 75% percentiles. The
error bars are the maximum value and the minimum value. The dotted line indicates the
mean value. DE = dry eye; NE = normal control eye.
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Figure 4.
Bar graphs showing quantitation of mRNA expression of cyclooxygenase-2 (COX-2),
prostaglandin E synthase (PGES), and prostaglandin D synthase (PGDS). C57B6 female
mice (n = 10) were housed in a dry eye (DE) chamber for 1 week. Five mice were killed at
days 3 and 7 after DE induction in each. mRNA was extracted from lacrimal glands (LGs)
and ocular surface (cornea and conjunctiva) after enucleation. Five control mice also were
killed. Using quantitative real-time polymerase chain reaction, the levels of COX-2, PGES,
and PGDS were measured at each time point (*P<0.05, **P<0.01, 1-way analysis of
variance). The error bars indicate the standard deviation.
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Figure 5.
Photomicrographs showing immunohistochemical staining results of cyclooxygenase-2
(COX-2) in the ocular surfaces and lacrimal glands. Mouse ocular tissue samples (n = 5)
were secured after 7 days in a dry eye chamber, and immunohistochemical staining was
performed using antimouse COX-2. Cyclooxygenase-2 expression patterns were determined
and compared with (A, B) healthy control mouse lacrimal glands, (C, D) meibomian glands,
(E, F) cornea, and (G, H) conjunctiva. The left column shows the staining pattern from a
representative healthy control mouse (n = 5). The middle and right columns show the
staining pattern from the dry eye mice (n = 5). The right column is a magnification of the
black box in the middle column. The white arrows (B) indicate ductal epithelial cell
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staining. The black arrows (F) and arrowheads (H) mark the COX-2–positive cells in the
cornea and conjunctiva, respectively.
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Figure 7.
Bar graphs showing cyclooxygenase-2 (COX-2) mRNA expression in the cornea and
lacrimal glands (LGs) after topical celecoxib treatment. C57B6 female mice (n = 20) were
housed in a dry eye chamber for 1 week. Then, celecoxib (0.1 µg/ml, 1.0 µg/ml, and 10.0 µg/
ml 3 times daily) was instilled in 1 eye for another week. Five mice in each group were
killed at 7 days after celecoxib treatment, and the cornea and LGs were removed. Five
control mice also were killed. mRNA extraction and quantitative polymerase chain reaction
for COX-2 were performed using the same protocols and primers as above (*P<0.05,
**P<0.01, 1-way analysis of variance). The error bars indicate the standard deviation.
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Table 2
Correlation of Ocular Irritation Scores and Concentration of Prostaglandin E2 and Prostaglandin D2 in Tears
Coefficient P Value R2
95% Confidence
Interval
PGE2 0.17 0.16 0.03 −0.07 to 0.41
PGD2 −0.17 0.11 0.04 −0.39 to 0.04
PGE2-to-PGD2 ratio 3.24 0.012* 0.18 0.75–5.74
PGD2 = prostaglandin D2; PGE2 = prostaglandin E2.
*P<0.05.
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Table 3
Immunohistochemical Staining of Prostaglandin Synthesizing Enzymes in Ocular Tissues
Cyclooxygenase-2 Prostaglandin E Synthase Prostaglandin D Synthase
Conjunctiva
  Epithelium ↑ ↑ ↑
  Stroma — — —
Cornea
  Epithelium ↑ — —
  Stroma — — —
  Endothelium — — —
Lacrimal gland
  Acina ↑ ↑ — —
  Ductal epithelium ↑ — —
  Periductal infiltrating cell — ↑ —
Meibomian gland
  Acina ↑ — ↓*
  Ductal epithelium — — —
↑ = elevated expression compared with normal control; — = not detected; ↑ ↑ = extensively elevated expression compared with normal control.
*
Especially decreased staining at nucleus.
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